Rentokil Initial (NYSE:RTO) Stock Rating Raised to Hold at Zacks Research

Key Points

• Zacks Research upgraded Rentokil Initial from “strong sell” to “hold,” matching the broader consensus rating. Analysts’ consensus price target is $31.90, with seven Buy, five Hold, and one Sell rating.
• RTO shares opened at $22.77 and remain well below their 52-week high of $34.67. Institutional investors own approximately 9.91% of the company.
• Recent developments include a $200 million share-buyback program and steady quarterly growth, though investors continue to monitor weakness in North America and the upcoming CFO transition.

Rentokil Initial (NYSE:RTO - Get Free Report) was upgraded by equities research analysts at Zacks Research from a "strong sell" rating to a "hold" rating in a research note issued on Thursday, Zacks reports.

A number of other analysts also recently weighed in on RTO. Wall Street Zen downgraded Rentokil Initial from a "buy" rating to a "hold" rating in a research report on Monday, July 20th. Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Rentokil Initial in a report on Monday, August 3rd. Investec upgraded Rentokil Initial to a "buy" rating in a research report on Wednesday, September 23rd. Stifel Nicolaus raised Rentokil Initial from a "hold" rating to a "buy" rating in a research note on Monday, October 5th. Finally, The Goldman Sachs Group reaffirmed a "buy" rating on shares of Rentokil Initial in a research note on Monday, October 5th. Seven research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Rentokil Initial presently has a consensus rating of "Hold" and a consensus price target of $31.90.

Rentokil Initial Stock Down 0.5%

NYSE RTO opened at $22.77 on Thursday. The company has a current ratio of 1.06, a quick ratio of 0.98 and a debt-to-equity ratio of 0.65. Rentokil Initial has a 1-year low of $19.50 and a 1-year high of $34.67. The company has a 50 day moving average of $21.95 and a 200-day moving average of $27.33.

Hedge Funds Weigh In On Rentokil Initial

A number of hedge funds have recently made changes to their positions in the stock. Continuum Advisory LLC bought a new stake in Rentokil Initial in the second quarter valued at approximately $42,000. V Square Quantitative Management LLC raised its holdings in Rentokil Initial by 84.5% during the 1st quarter. V Square Quantitative Management LLC now owns 1,395 shares of the company's stock worth $44,000 after purchasing an additional 639 shares during the last quarter. Integrated Wealth Concepts LLC bought a new position in Rentokil Initial during the 2nd quarter worth approximately $57,000. Parallel Advisors LLC lifted its position in shares of Rentokil Initial by 50.5% in the 1st quarter. Parallel Advisors LLC now owns 2,107 shares of the company's stock worth $66,000 after purchasing an additional 707 shares during the period. Finally, Fifth Third Bancorp acquired a new position in shares of Rentokil Initial in the 1st quarter worth approximately $83,000. 9.91% of the stock is currently owned by institutional investors.

Rentokil Initial News Summary

Here are the key news stories impacting Rentokil Initial this week:

• Positive Sentiment: Share buyback supports the stock: Rentokil announced a $200 million share repurchase program, expected to begin shortly and be completed before full-year results. The buyback follows the $230 million sale of SOLitude Lake Management and should provide additional demand for the shares. Rentokil announces $200 million share buyback as third-quarter organic revenue grows 3.4%
• Positive Sentiment: Steady quarterly performance: Third-quarter revenue increased 4.0% to $1.89 billion, with organic revenue growth of 3.4%. Management maintained its expectation that 2026 profit will be in line with market forecasts, reducing near-term earnings risk. Rentokil announces $200 million buyback; quarterly revenue rises on improving North America business
• Positive Sentiment: North American outlook improves: UBS raised its price target to 390p from 370p and reiterated a “buy” rating, citing signs that performance in Rentokil’s key North American pest-control business is stabilizing. Rentokil's price target raised by UBS as North America shows signs of stabilising
• Neutral Sentiment: Finance leadership transition: CFO Paul Edgecliffe-Johnson plans to retire on January 31. The departure adds a transition factor for investors, although no deterioration in current-year guidance was reported. Rentokil Initial CFO Paul Edgecliffe-Johnson To Retire From Jan 31
• Negative Sentiment: Persistent North American concerns: Broyhill Asset Management argued that weakness in North America undermines the investment case, highlighting the risk that stabilization may not yet translate into sufficiently strong growth or earnings momentum. Rentokil Initial plc North American weakness undermines the thesis
• Negative Sentiment: Longer-term strategic questions: Commentary has raised concerns about whether artificial intelligence could disrupt parts of Rentokil’s growth strategy, adding uncertainty beyond the company’s near-term results. AI Disruption Raises New Questions for Rentokil’s Growth Strategy

Rentokil Initial Company Profile

Rentokil Initial plc NYSE: RTO is a business services company headquartered in the United Kingdom. It provides pest control, hygiene, and workplace services to commercial, public-sector, and residential customers. Its offerings are designed to help organizations manage pests, maintain sanitary environments, and support health, safety, and workplace standards.

The company's pest control services address insects, rodents, and other pests, while its hygiene operations provide washroom services, sanitary products, air care, floor-care solutions, and related workplace services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.